Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review

被引：30

作者：

Ascierto, Paolo A. ^{[1
]}

Gogas, Helen J. ^{[2
,3
]}

Grob, Jean Jacques ^{[4
]}

Martin Algarra, Salvador ^{[5
]}

Mohr, Peter ^{[6
]}

Hansson, Johan ^{[7
,8
]}

Hauschild, Axel ^{[9
,10
]}

机构：

[1] Ist Nazl Studio & Cura Tumori Fdn G Pascale, Unit Melanoma Canc Immunotherapy & Innovat Therap, I-80131 Naples, Italy

[2] Univ Athens, Dept Internal Med 1, Athens, Greece

[3] Univ Athens, Sch Med, GR-11527 Athens, Greece

[4] Aix Marseille Univ, Serv Dermatol, Hop Timone, Marseille, France

[5] Univ Navarra, Dept Oncol, E-31080 Pamplona, Spain

[6] Elbeklinikum Buxtehude, Dept Dermatol, Buxtehude, Germany

[7] Karolinska Inst, Karolinska Univ Hosp Solna, Dept Oncol Pathol, Stockholm, Sweden

[8] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden

[9] Univ Hosp Schleswig Holstein, Dept Dermatol Venereol & Allergol, Kiel, Germany

[10] Univ Hosp Schleswig Holstein, Dept Dermatol, Kiel, Germany

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2013年 / 85卷 / 02期

关键词：

Adjuvant; Disease-free survival; Immunomodulation; Interferon alfa-2a; Interferon alfa-2b; Malignant melanoma; Peginterferon alfa-2b; Survival; HIGH-DOSE INTERFERON-ALPHA-2B; HIGH-RISK MELANOMA; ONCOLOGY-GROUP TRIAL; REGULATORY T-CELLS; CUTANEOUS MELANOMA; PROGNOSTIC-SIGNIFICANCE; METASTATIC MELANOMA; PREDICTIVE MARKER; RESECTED MELANOMA; III MELANOMA;

D O I：

10.1016/j.critrevonc.2012.07.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Interferon alfa (IFN alpha) and pegylated IFN alpha 2b (PegIFN alpha 2b) are the only agents currently approved for the adjuvant treatment of resected melanoma at high risk of recurrence. Meta-analyses showed statistically significant disease-free survival (DFS) and overall survival (OS) benefits versus controls but did not clarify optimal dose/duration. We review data from all recent clinical trials to provide the latest information on dose, duration, and potential predictive factors of treatment success. Recent data largely confirm DFS and OS benefits but optimal dose/duration is not clarified. The data suggest greater responses in patients with stage III micro-metastatic versus macro-metastatic disease, and ulceration may also predict greater sensitivity to therapy, although further investigation is needed. Presently, IFN alpha and PegIFN alpha 2b remain valid adjuvant therapies following resection of high-risk melanoma; the most appropriate treatment regimen should be determined on an individual patient basis according to patient lifestyle and approach, potential for toxicity, and the available clinical evidence. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

引用

页码：149 / 161

页数：13

共 61 条

[1]

Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697) [J].

Agarwala, S. S. ;

Lee, S. J. ;

Flaherty, L. E. ;

Smylie, M. ;

Kefford, R. F. ;

Carson, W. E. ;

Cohen, G. ;

Kirkwood, J. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[2]

Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease [J].

Anaya, Daniel A. ;

Xing, Yan ;

Feng, Lei ;

Huang, Xuelin ;

Camacho, Luis H. ;

Ross, Merrick I. ;

Gershenwald, Jeffrey E. ;

Lee, Jeffrey E. ;

Mansfield, Paul F. ;

Cormier, Janice N. .

CANCER, 2008, 112 (09) :2030-2037

[3]

Ascierto PA, 2000, CANCER-AM CANCER SOC, V89, P1490, DOI 10.1002/1097-0142(20001001)89:7<1490::AID-CNCR11>3.0.CO

[4]

2-V

[5]

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment [J].

Ascierto, Paolo A. ;

Napolitano, Maria ;

Celentano, Egidio ;

Simeone, Ester ;

Gentilcore, Giusy ;

Daponte, Antonio ;

Capone, Mariaelena ;

Caraco, Corrado ;

Calemma, Rosa ;

Beneduce, Gerardo ;

Cerrone, Margherita ;

De Rosa, Vincenzo ;

Palmieri, Giuseppe ;

Castello, Giuseppe ;

Kirkwood, John M. ;

Marincola, Francesco M. ;

Mozzillo, Nicola .

JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8

[6]

Adjuvant therapy of melanoma with interferon: lessons of the past decade [J].

Ascierto, Paolo A. ;

Kirkwood, John M. .

JOURNAL OF TRANSLATIONAL MEDICINE, 2008, 6 (1)

[7]

Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[8]

Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952 [J].

Bouwhuis, M. G. ;

Suciu, S. ;

Kruit, W. ;

Sales, F. ;

Stoitchkov, K. ;

Patel, P. ;

Cocquyt, V. ;

Thomas, J. ;

Lienard, D. ;

Eggermont, A. M. M. ;

Ghanem, G. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (03) :361-368

[9]

Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18 952) and prognostic value on treatment outcome [J].

Bouwhuis, Marna G. ;

Collettee, Sandra ;

Suciu, Stefan ;

de Groot, Els R. ;

Kruit, Wim H. ;

ten Hagen, Timo L. M. ;

Aarden, Lucien A. ;

Eggermont, Alexander M. M. ;

Swaak, Antonius J. G. .

MELANOMA RESEARCH, 2011, 21 (04) :344-351

[10]

Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies-EORTC 18991 [J].

Bouwhuis, Marna G. ;

Suciu, Stefan ;

Testori, Alessandro ;

Kruit, Wim H. ;

Sales, Francois ;

Patel, Poulam ;

Punt, Cornelis J. ;

Santinami, Mario ;

Spatz, Alain ;

ten Hagen, Timo L. M. ;

Eggermont, Alexander M. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) :2460-2466

← 1 2 3 4 5 6 7 →